Home › Neoplasm ayon sa Histologic Type › New Jersey
Pag-aaral pangklinika para sa Neoplasm ayon sa Histologic Type sa New Jersey
6 pag-aaral para sa Neoplasm ayon sa Histologic Type ang naghahanap ng mga kalahok sa mga site sa New Jersey.
Mga Lungsod sa New Jersey
Opisyal na teksto ng pag-aaral (English)
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- MD Anderson Cancer Center at Cooper, Camden
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT04198766uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- Rutgers, New Brunswick
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT05874921A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07075185Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06001788Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT07216443Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
- Inspira Medical Center Mullica Hill, Mullica Hill
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT06463665Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.